37+ years in virus research; PhD in Biochemistry from WesternUniversity, post- doctoral research in Dr. Ira Pastan’s lab, NCI and was Director of the Gene Therapy Program at NorthShore University HealthSystem., Evanston, Il; Dr. Seth developed several novel therapies for cancer treatment and focused on innovative gene therapy/immunotherapy approaches using oncolytic viruses.
Receiving his Ph.D in Department of Molecular Physiology and Biophysics, University of Iowa, Dr. Xu explored the cross-disciplinary field of translational medicine. Becoming an expert in cancer gene therapy while working with Dr. Seth. His work has increased therapeutic efficacy of oncolytic viruses. Currently he is a principal investigator at NorthShore University Health System, a teaching affiliate of University of Chicago.
27+ years experience in life science and cancer research operations and administration. Member of the founder team, Rosetta Inpharmatics; member of the strategic development founder team, Seattle Cancer Care Alliance; division administrator of molecular pharmacology at Fred Hutchinson Cancer Research Center and director of affiliate network, Seattle Cancer Care Alliance.
Expansive lead role in multiple cancer drug FDA approvals, expert in hematologic malignancies (non-hodgkins, hodgkins lymphomas, acute and chornic leukemias), focused on systemic and cutaneous T-cell lymphomas; pivotal member of the immunotherapy program at Fred Hutchinson Cancer Research Center; founder of T-cell leukemia lymphoma foundation.
Seasoned executive and leader in drug development, currently Executive VP and Corporate Strategy for Seattle Genetics. Received her PharmD at the University of Washington, Sr. Oncology Medical Scientist for GSK. Named as top woman executive and leader in the life science industry.
Pioneer in cellular immune therapy and knowledge-expert on oncolytic viruses; trained at the Rosenberg Labs; Professor of Surgery with Tenure at University of Illinois, College of Medicine.
Copyright © 2022 Amunbio - All Rights Reserved.